Medicines Consent Notices




182 NEW ZEALAND GAZETTE No. 7

Product:
Active Ingredient(s):
Troglitazone 400mg
Dosage Form:
Film coated tablet
NZ Sponsor:
Parke Davis (Div. Warner Lambert NZ Limited)
Manufacturer(s):
Warner Lambert Inc., Vega Baja, Puerto Rico

Rezulin

Product:
Active Ingredient(s):
Oseltamivir phosphate 98.5mg equivalent to 75mg oseltamivir
Dosage Form:
Capsule
NZ Sponsor:
Roche Products (New Zealand) Limited
Manufacturer(s):
F Hoffmann-La Roche AG, Head Office and manufacturing site, Basle, Switzerland

Tamiflu

Product:
Active Ingredient(s):
Rofecoxib 2.5mg/mL
Dosage Form:
Oral suspension
NZ Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer(s):
Merck & Co Inc., Merck Manufacturing Division, West Point, Pennsylvania, United States of America

Vioxx

Product:
Active Ingredient(s):
Rofecoxib 5mg/mL
Dosage Form:
Oral suspension
NZ Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer(s):
Merck & Co Inc., Merck Manufacturing Division, West Point, Pennsylvania, United States of America

Vioxx

Product:
Active Ingredient(s):
Rofecoxib 12.5mg
Dosage Form:
Tablet
NZ Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer(s):
Merck Manufacturing Division of Merck and Co, Bo. Sabana Hoyos, Arecibo, Puerto Rico
Merck Sharp and Dohme, South Granville, New South Wales, Australia

Vioxx

Product:
Active Ingredient(s):
Rofecoxib 25mg
Dosage Form:
Tablet
NZ Sponsor:
Merck Sharp & Dohme (New Zealand) Limited
Manufacturer(s):
Merck Manufacturing Division of Merck and Co, Bo. Sabana Hoyos, Arecibo, Puerto Rico
Merck Sharp and Dohme, South Granville, New South Wales, Australia

Dated this 21st day of January 2000.

G. R. BOYD, Chief Advisor, Safety and Regulation, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.


Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the schedule hereto:

Schedule

Product:
Active Ingredient(s):
Influenza virus haemagglutinin type A/Beijing/262/95-like (H1N1) 30µg/mL
Influenza virus haemagglutinin type A/Sydney/5/97-like (H3N2) 30µg/mL
Influenza virus haemagglutinin type B/Beijing/184/93-like 30µg/mL
Dosage Form:
Suspension for injection
NZ Sponsor:
SmithKline Beecham (NZ) Limited
Manufacturer(s):
Sächsisches Serumwerk Dresden, Branch of SKB Pharma GmbH, Dresden, Germany
SmithKline Beecham Biologicals SA, Rixensart, Belgium

Fluarix

Dated this 21st day of January 2000.

G. R. BOYD, Chief Advisor, Safety and Regulation, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2000, No 7


Gazette.govt.nz PDF NZ Gazette 2000, No 7





✨ LLM interpretation of page content

🏥 Consent to the Distribution of New Medicines

🏥 Health & Social Welfare
21 January 2000
Medicines, Consent, Troglitazone, Oseltamivir phosphate, Rofecoxib
  • G. R. Boyd, Chief Advisor, Safety and Regulation

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
21 January 2000
Medicines, Consent, Influenza virus haemagglutinin
  • G. R. Boyd, Chief Advisor, Safety and Regulation